Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
02
2019
accepted:
30
07
2019
entrez:
22
8
2019
pubmed:
23
8
2019
medline:
4
3
2020
Statut:
epublish
Résumé
Chagas disease, a vector-borne parasitosis caused by Trypanosoma cruzi, is endemic to Latin America and has spread to other countries due to immigration of infected persons. It is estimated that 160,000 people are infected in Chile, most of them in the chronic phase and without etiological treatment. The infection is confirmed by conventional serological methods while molecular methods have become in valuable tools to evaluate parasitemia in treated and non-treated chronic Chagas disease patients. The objective of this study was to determine, by conventional Polymerase Chain Reaction, the presence of T. cruzi kinetoplastid DNA in peripheral blood samples from 114 adult individuals with confirmed chronic Chagas disease, before and 6.6 years (average) after treatment with nifurtimox. The samples were received and preserved in guanidine-EDTA until DNA purification. Conventional PCR assays were performed in triplicate with T. cruzi kinetoplastid DNA primers 121 and 122. The amplified products were fractionated by electrophoresis in 2% agarose gels. A 330 bp product represented a positive assay. 84.2% (96 cases) and 6.1% (7 cases) of the samples taken before and after the treatment, respectively, were positive. The McNemar test showed a statistically significant difference between the groups of samples (p<0.001). Since serological negativization (the current cure criterion) delay many years after therapy and positive parasitological results represent a treatment failure, the conversion of pre-therapy positive conventional PCR is a qualitative and complementary tool that could be included in protocols of prolonged follow-up.
Identifiants
pubmed: 31433828
doi: 10.1371/journal.pone.0221100
pii: PONE-D-19-03206
pmc: PMC6703690
doi:
Substances chimiques
DNA, Protozoan
0
Nifurtimox
M84I3K7C2O
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221100Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Drug Des Devel Ther. 2010 Sep 24;4:243-53
pubmed: 20957215
N Engl J Med. 2011 Jun 30;364(26):2527-34
pubmed: 21714649
Circulation. 2007 Mar 6;115(9):1109-23
pubmed: 17339569
Eur J Clin Microbiol Infect Dis. 2016 Nov;35(11):1819-1827
pubmed: 27488437
BMC Infect Dis. 2013 Feb 13;13:85
pubmed: 23406191
Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):300-16
pubmed: 20109600
Rev Chilena Infectol. 2017 Apr;34(2):120-127
pubmed: 28632825
J Mol Diagn. 2017 Sep;19(5):673-681
pubmed: 28727985
J Antimicrob Chemother. 2001 Oct;48(4):515-9
pubmed: 11581230
Korean J Parasitol. 2019 Feb;57(1):39-41
pubmed: 30840798
Lancet Infect Dis. 2013 Apr;13(4):342-8
pubmed: 23395248
PLoS Negl Trop Dis. 2011 Jan 11;5(1):e931
pubmed: 21264349
Am J Trop Med Hyg. 1994 Dec;51(6):771-7
pubmed: 7810810
Comput Struct Biotechnol J. 2016 Dec 14;15:98-103
pubmed: 28066534
Front Immunol. 2018 Aug 06;9:1842
pubmed: 30127792
Infect Dis Clin North Am. 2012 Jun;26(2):275-91
pubmed: 22632639
Trop Med Int Health. 2012 Mar;17(3):368-73
pubmed: 22212647
Mem Inst Oswaldo Cruz. 2001 Aug;96(6):823-6
pubmed: 11562709
Ann Trop Med Parasitol. 2008 Sep;102(6):481-7
pubmed: 18782487
Acta Trop. 2016 Apr;156:1-16
pubmed: 26747009
J Antimicrob Chemother. 2010 Aug;65(8):1759-64
pubmed: 20542903
Int J Parasitol. 2001 May 1;31(5-6):550-4
pubmed: 11334941
PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006814
pubmed: 30383777
BMC Infect Dis. 2010 Nov 25;10:337
pubmed: 21108793
Rev Panam Salud Publica. 2015 Jan;37(1):38-43
pubmed: 25791186
Mol Biochem Parasitol. 1988 Jan 1;27(1):63-70
pubmed: 2830509